CLI-2, células linfoides innatas tipo 2.
Bibliografia: 1. Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2(3):110. doi:10.4172/2155-9899.1000110 2.
Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J
Allergy Clin Immunol. 2012;130(6):1344-1354. 3. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis—part II: immune
cell subsets and therapeutic concepts. J Allergy Clin Immunol. 2011;127(6):1420-1432. 4. Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of
biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135(2):324-336. 5. Guttman-Yassky E, Dhingra N, Leung DYM. New era of biologic
therapeutics in atopic dermatitis. Expert Opin Biol Ther. 2013;13(4):549-561. 6. Biedermann T, Skabytska Y, Kaesler S, Volz T. Regulation of T cell immunity in atopic
dermatitis by microbes: the yin and yang of cutaneous inflammation. Front Immunol. 2015;6:353. doi:10.3389/fimmu.2015.00353 7. Palomares O, Akdis M, Martín-Fontecha
M, Akdis CA. Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells. Immunol Rev. 2017;278(1):219-236. 8. Weidinger S, Beck LA, Bieber T,
Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi:10.1038/s41572-018-0001-z 9. Rerknimitr P, Otsuka A, Nakashima C, Kabashima K. The
etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regen. 2017;37:14. doi:10.1186/s41232-017-0044-7 10. Brunner PM,
Guttman-Yassky E, Leung DYM. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4):S65-S76. 11.
Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.